
via NIH
American and European researchers publish study in Nature Medicine reporting a new, single treatment option for cystic fibrosis patients
Researchers from the George Washington University (GW), the University of Perugia, and the University of Rome have discovered a potential new drug to treat and stop the progression of cystic fibrosis. Thymosin ?1 (T?1) is a novel therapeutic single molecule-based therapy that not only corrects genetic and tissue defects, but also significantly reduces inflammation seen in cystic fibrosis patients.
“Right now there are multiple treatments for cystic fibrosis, and while these have improved life expectancy dramatically, there is still only a lifespan of about 40 years for patients. No one treatment can stand alone,” said Allan L. Goldstein, Ph.D., co-author of the paper and Professor Emeritus in Residence of Biochemistry and Molecular Medicine at the GW School of Medicine and Health Sciences. “We developed a single treatment that can potentially correct the genetic defect that causes cystic fibrosis and decrease the inflammation that happens as a result.”
Cystic fibrosis is a genetic disease that causes persistent lung infections and limits the ability to breathe over time, and it affects approximately 70,000 worldwide and 30,000 in the U.S. alone. Cystic fibrosis is the result of mutations in the gene encoding the protein called the cystic fibrosis transmembrane conductance regulator (CFTR), which is important to maintain chloride-channel activity affecting the salt and water balance in the lungs. This mutation results in a misfolded CFTR protein, and its premature degradation leads to impaired chloride permeability and persistent lung inflammation.
Goldstein and co-authors Luigina Romani, Ph.D., M.D., at the University of Perugia and Enrico Garaci, M.D., at the University of Rome “San Raffaele,” both in Italy, published their results in Nature Medicine. They report that T?1, a synthetic version of a naturally occurring peptide first isolated from the thymus, corrects the multiple tissue defects found in the lungs and small intestines in a mouse model of cystic fibrosis, as well as the defects in the CFTR seen in cells isolated from cystic fibrosis patients. T?1 not only significantly reduces the inflammation seen in cystic fibrosis, but also increases CFTR maturation, stability, and activity. Due to this two-pronged action, T?1 offers a strong potential to be a single-molecule therapeutic agent to treat and stop the progression of cystic fibrosis.
Goldstein and colleagues first isolated and characterized T?1 as a biological response modifier with potent immune therapeutic activity in 1979. This research was done in large part at GW. Although the peptide is produced in small amounts in several peripheral lymphoid and non-lymphoid tissues, the highest concentrations of T?1 are found in the thymus. T?1, whose commercial name is Zadaxin, has been approved for clinical use for over 15 years in 35 countries in the treatment of patients with viral infections, immunodeficiency diseases, malignancies, and HIV/AIDS. Though not currently available in the U.S., it has an excellent safety profile and does not induce the side effects and toxicities commonly associated with most immunomodulatory agents.
Learn more: Research Uncovers Potential New Treatment to Treat and Stop Progression of Cystic Fibrosis
[osd_subscribe categories=’cystic-fibrosis’ placeholder=’Email Address’ button_text=’Subscribe Now for any new posts on the topic “CYSTIC FIBROSIS”‘]
The Latest on: Cystic fibrosis
[google_news title=”” keyword=”cystic fibrosis” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cystic fibrosis
- Newly identified stem cell variants drive inflammation in cystic fibrosis patientson September 28, 2023 at 5:20 pm
Two nationally recognized experts in cloning and stem cell science from the University of Houston, Wa Xian and Frank McKeon, are reporting that five lung stem cell variants dominate the lungs of ...
- Cystic Fibrosis Therapeutics Market Aims for US$ 116.42 Billion Valuation by 2033 in Reviving Respiratory Healthon September 28, 2023 at 12:00 am
In 2023, the global Cystic Fibrosis Therapeutics Market is expected to be worth US$ 12.5 billion. The overall demand for Cystic Fibrosis is expected to grow at a CAGR of 25.0% between 2023 and 2033, ...
- ‘Breathe Free Ride Hard’ presents $15K check to Cystic Fibrosis Foundationon September 27, 2023 at 8:01 pm
CHICOPEE, Mass. (WWLP) – An evening of memorable charitable giving in Chicopee to help in the fight against cystic fibrosis, a genetic condition that damages your lungs, digestive tract, and other ...
- Researchers Discover Disease-Causing Stem Cells in Lungs of Cystic Fibrosis Patientson September 27, 2023 at 12:07 pm
Cystic fibrosis is an inherited and progressive disease that causes long-lasting lung infections and limits the ability to breathe. It is caused by a defect in a gene called the cystic fibrosis ...
- Silicon Valley High School Senior Works to Improve Cystic Fibrosis Research through AIon September 27, 2023 at 5:19 am
She’s also the founder and CEO of Nysha.ai, a nationally-recognized nonprofit organization committed to raising awareness for cystic fibrosis. For the past few years, Pinnaka has worked on numerous ...
- Arcturus Therapeutics extends cystic fibrosis treatment dealon September 27, 2023 at 3:21 am
Arcturus Therapeutics has extended an existing agreement with the Cystic Fibrosis (CF) Foundation for advancing ARCT-032. ARCT-032 is an investigational messenger ribonucleic acid (mRNA) therapy that ...
- Cystic Fibrosis Newson September 24, 2023 at 5:00 pm
25, 2023 — High levels of some minerals and metals in environmental water supplies may increase the risk of nontuberculous mycobacteria (NTM) pulmonary infections in people with cystic fibrosis ...
- A breakthrough cystic fibrosis drug gave them the gift of time. But miracles come with complications.on September 20, 2023 at 8:38 am
It’s been truly miraculous,” said J. Samuel Pope, director of the adult cystic fibrosis program at Hartford Hospital. “We used to have five to seven patients at any one time in the hospital. Now it’s ...
- Three siblings with cystic fibrosis bonded over daily struggles. Then came a breakthrough drug.on September 20, 2023 at 6:20 am
Cystic fibrosis drug Trikafta helps most but not all with the deadly genetic disease Cystic fibrosis miracle drug Trikafta, helps 90% of people, the other 10% are still waiting for their aid.
via Bing News